How did a biotech company that almost ran out of money three times get acquired for over $3 billion? Will the M&A streak continue? And why are drugmakers working with a telehealth company called Prescribery?
We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s weekly biotech podcast. Venture capitalist Bryan Roberts joins us to discuss his firm’s investment in Kelonia Therapeutics, the CAR-T biotech that Eli Lilly just said it would buy for $3.25 billion.
We also bring on our colleague Katie Palmer to talk through her story about pharma companies using bargain-basement telehealth providers to drive drug prescriptions and sales.
To read about Lilly’s acquisition of Kelonia and the biotech’s initial investment pitch, go here.; to read more about pharma companies’ new strategy with telehealth, go here; and for more on Medicare delaying its obesity drug coverage pilot, go here.
Be sure to sign up for “The Readout LOUD” on Apple Podcasts, Spotify, or wherever you get your podcasts.
